Research suggests that a new type of antipsychotic, xanomeline and trospium chloride (Cobenfy), is associated with significant improvements in cognitive symptoms among people with schizophrenia.

Pakistan will take on New Zealand in the opening match of the ODI Tri-Series. This match will be played at Gadaffi Stadium in Lahore. Pakistan is set to host South Africa and New Zealand in a Tri ...

The company successfully launched Cobenfy, a novel treatment for schizophrenia, marking a significant milestone in their neuroscience portfolio. Operational excellence and financial discipline led ...

Due to a spike in respiratory viruses such as influenza, COVID-19 and Respiratory Syncytial Virus Infection (RSV), Union Health is now restricting visitation in its neonatal intensive care unit.

Pipeline readouts that could help drive long-term growth span several programs, but we see the highest potential in schizophrenia drug Cobenfy (data later this year for combination use ...

Shares of Bristol Myers fell to $58.08. The stock is up around 25% over the past year, driven in part by investor enthusiasm for its new schizophrenia drug Cobenfy, which was approved by the FDA last ...

The company celebrated significant milestones in its product pipeline, notably the FDA approval of Cobenfy and the promising regulatory path of Opdivo-related treatments. These achievements ...

Bristol Myers added that it expected the U.S. approval last year of its Cobenfy treatment for patients with schizophrenia would be a driver of growth. The company also said it was expanding a ...

The top 10 biopharma M&A deals of 2023 The company is counting heavily on Cobenfy, which was approved in September and was the crown jewel of the $14 billion buyout of Karuna. BMS reported sales ...

We also achieved the landmark U.S. approval of Cobenfy last year for the treatment of schizophrenia in adults, and we expect this medicine to have a meaningful impact on patients and the company as a ...

The stock is up around 25% over the past year, driven in part by investor enthusiasm for its new schizophrenia drug Cobenfy, which was approved by the FDA last September. The new forecast draws ...